ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients (ACTivate)
Anthony Sung, MD
Summary
This study is a phase 2, multicenter, randomized controlled trial to test the application of Acceptance and Commitment Therapy (ACT) in HCT patients. ACT is an evidence-based cognitive behavioral therapy intervention that emphasizes psychological flexibility and behaviors, helping transplant patients focus on actions that may help maintain adequate physical activity despite physical and emotional discomfort.
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- Yes
Patient Inclusion Criteria: * Ability of participant to understand this study, and participant willingness to sign a written informed consent. NOTE: Remote / electronic consent via REDCap consenting allowed per IRB policy and approval. * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Plan to undergo allogeneic HCT in approximately 30 days * Males and/or females age 18 - 80 years * Agreement to adhere to Lifestyle Considerations throughout study duration * Access to necessary resources for participating in a…
Interventions
- BehavioralACTivate sessions
ACTivate sessions are based on ACT and train psychological flexibility skills to help patients and caregivers adhere to recommendations for physical activity and nutrition in the face of an uncertain and difficult treatment course, side effects and complications. Sessions will be conducted conjointly (include both the patient and caregiver). . Interventionists will be master's level psychology professionals. All sessions will be conducted remotely and audiotaped.
Locations (2)
- University of Kansas Cancer CenterKansas City, Kansas
- Duke UniversityDurham, North Carolina